Bmx-CreERT2 Mouse

Random Transgenic

Bmx-CreERT2 Random Transgenic Mouse Model
This line is cryopreserved and requires cryorecovery.

C57BL/6J Background

  • Model #
  • Genotype
  • Nomenclature
  • 14081-F
    C57BL/6J-Tg(Bmx-cre/ERT2)1Rha
  • 14081-M
    C57BL/6J-Tg(Bmx-cre/ERT2)1Rha
  • An inducible cre deleter under the control of the BMX non-receptor tyrosine kinase promoter.
  • Cre recombination is inducible via administration of tamoxifen.
  • Useful for study of angiogenesis, atherosclerosis and neovascularization.
  • Non-induced Bmx-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Bmx-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in endothelial cells (95%+).

Genetic Background:

C57BL/6J

Origin:

The Bmx-Cre-ERT2 mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Bmx promoter fragment fused to a CreERT2 cDNA into B6xCBA F1 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2015.


Source:

Cancer Research Technology (CRT)

Species:

Mouse

Access to this model requires execution of a Limited Breeding Agreement and cryorecovery services to recover the line. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users. Cryorecovery fees are additional.

Purchase of line #14081 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.